Epidemiology of invasive meningococcal disease in the Netherlands, 1960–2012: an analysis of national surveillance data

2014 ◽  
Vol 14 (9) ◽  
pp. 805-812 ◽  
Author(s):  
Merijn W Bijlsma ◽  
Vincent Bekker ◽  
Matthijs C Brouwer ◽  
Lodewijk Spanjaard ◽  
Diederik van de Beek ◽  
...  
Keyword(s):  
The Netherlands ◽  
Meningococcal Disease ◽  
Surveillance Data ◽  
Invasive Meningococcal Disease ◽  
National Surveillance

scholarly journals The Clinical Picture and Severity of Invasive Meningococcal Disease Serogroup W Compared With Other Serogroups in the Netherlands, 2015–2018

2019 ◽  
Vol 70 (10) ◽  
pp. 2036-2044 ◽  
Author(s):  
Anna D Loenenbach ◽  
Arie van der Ende ◽  
Hester E de Melker ◽  
Elisabeth A M Sanders ◽  
Mirjam J Knol
Keyword(s):  
The Netherlands ◽  
Meningococcal Disease ◽  
Clinical Picture ◽  
Disease Onset ◽  
Clinical Manifestations ◽  
Case Fatality ◽  
Invasive Meningococcal Disease ◽  
Almost All ◽  
Specific Symptoms ◽  
Host Characteristics

Abstract Background An increase in invasive meningococcal disease (IMD) serogroup W (IMD-W) cases caused by sequence type-11 clonal complex (cc11) was observed from October 2015 in the Netherlands. We compared the clinical picture and disease outcome of IMD-W cases with other serogroups, adjusting for host characteristics. Methods We included IMD cases reported from January 2015 to June 2018 in the Netherlands and assessed clinical manifestation and symptoms at disease onset and calculated case fatality rates (CFRs). We used logistic regression to compare clinical manifestations and mortality of IMD-W with IMD caused by meningococci serogroup B, Y, or C, adjusting for age, gender, and comorbidities. Results A total of 565 IMD cases were reported, of which 204 were IMD-W, 270 IMD-B, 63 IMD-Y, and 26 IMD-C. Most IMD-W isolates belonged to cc11 (93%; 175/188). Compared with other serogroups, IMD-W patients were diagnosed more often with septicemia (46%) or pneumonia (12%) and less often with meningitis (17%, P < .001). IMD-W cases presented more often with respiratory symptoms (45%, P < .001); 16% of IMD-W patients presented with diarrhea without IMD-specific symptoms (P = .061). The CFR for IMD-W was 16% (32/199, P < .001). The differences between IMD-W and other serogroups remained after adjusting for age, gender, and comorbidities. Conclusions The atypical presentation and severe outcome among IMD-W cases could not be explained by age, gender, and comorbidities. Almost all our IMD-W cases were caused by cc11. More research is needed to identify the bacterial factors involved in clinical presentation and severity of IMD-W cc11.

Predicted coverage by 4CMenB vaccine against invasive meningococcal disease cases in the Netherlands

Vaccine ◽  
2020 ◽  
Vol 38 (49) ◽  
pp. 7850-7857
Author(s):  
W. Freudenburg-de Graaf ◽  
M.J. Knol ◽  
A. van der Ende
Keyword(s):  
The Netherlands ◽  
Meningococcal Disease ◽  
Invasive Meningococcal Disease ◽  
4Cmenb Vaccine

scholarly journals Evaluation of the surveillance system for invasive meningococcal disease (IMD) in the Netherlands, 2004 – 2016

2019 ◽  
Author(s):  
Diederik A.H. Brandwagt ◽  
Arie van der Ende ◽  
Helma (W.) L.M. Ruijs ◽  
Hester E. de Melker ◽  
Mirjam J. Knol
Keyword(s):  
Public Health ◽  
The Netherlands ◽  
Meningococcal Disease ◽  
Surveillance System ◽  
National Level ◽  
Vaccination Status ◽  
Invasive Meningococcal Disease ◽  
Reference Laboratory ◽  
Public Health Response ◽  
Notification Data

Abstract Background Enhanced surveillance for confirmed cases of invasive meningococcal disease (IMD) was introduced in the Netherlands in 2003, in which reference laboratory data (NRLBM) are linked with notification data (OSIRIS). The quality of surveillance information is important for public health decision making. Our objective was to describe the system and evaluate it for data completeness and timeliness.
Methods
Cases reported in the surveillance system from 2004 to 2016 were included. For the notification data, we used information on serogroup, vaccination status, mortality, and country of infection as indicators for record completeness. Notification times to regional and national level were calculated using the reported dates available in the notification database. 
Results
A total of 2,123 cases were reported in the years 2004-2016, of which 1.968 (93%) were reported by the reference laboratory and 1.995 (94%) in the notification system. Of all cases, 1.840 cases (87%) were reported in both systems and could be linked. The serogroup was known in 86% of the notified cases, and was significantly higher (94%) in the years 2013-2016. Information on vaccination status, mortality and country of infection was available in 88%, 99% and 97% of notified cases, respectively. Regional notification of cases occurred within one working day for 86% of cases and 98% were notified nationally within three days. 
Conclusions
A well performing IMD surveillance system was demonstrated and serogroup completeness has improved over the years. Underlining the need for reporting to both the clinical and laboratory surveillance system remains important to further improve the overall performance in supporting public health response and vaccination policy.

scholarly journals Implementation of MenACWY vaccination because of ongoing increase in serogroup W invasive meningococcal disease, the Netherlands, 2018

2018 ◽  
Vol 23 (16) ◽  
Author(s):  
Mirjam J Knol ◽  
Wilhelmina LM Ruijs ◽  
Laura Antonise-Kamp ◽  
Hester E de Melker ◽  
Arie van der Ende
Keyword(s):  
The Netherlands ◽  
Incidence Rate ◽  
Meningococcal Disease ◽  
Case Fatality Rate ◽  
Clonal Complex ◽  
Case Fatality ◽  
Annual Incidence ◽  
Invasive Meningococcal Disease ◽  
Fatality Rate ◽  
Annual Incidence Rate

The annual incidence rate of serogroup W invasive meningococcal disease in the Netherlands increased from < 0.05/100,000 (n < 10) before 2015 to 0.5/100,000 (n = 80) in 2017. Most isolates (94%) belong to clonal complex 11. The incidence rate is highest among  < 5 year-olds and 15–24 year-olds. The case fatality rate was 12% (17/138) in 2015–2017. From May 2018, MenACWY vaccination replaces MenC vaccination at age 14 months and from October 2018, 13–14 year-olds are offered MenACWY vaccination.

Disease Burden of Invasive Meningococcal Disease in the Netherlands Between June 1999 and June 2011: A Subjective Role for Serogroup and Clonal Complex

2015 ◽  
Vol 61 (8) ◽  
pp. 1281-1292 ◽  
Author(s):  
Susanne P. Stoof ◽  
Gerwin D. Rodenburg ◽  
Mirjam J. Knol ◽  
Lidewij W. Rümke ◽  
Sandra Bovenkerk ◽  
...  
Keyword(s):  
The Netherlands ◽  
Meningococcal Disease ◽  
Disease Burden ◽  
Clonal Complex ◽  
Invasive Meningococcal Disease

scholarly journals Evaluation of the surveillance system for invasive meningococcal disease (IMD) in the Netherlands, 2004 – 2016

2019 ◽  
Author(s):  
Diederik A.H. Brandwagt ◽  
Arie van der Ende ◽  
Helma (W.) L.M. Ruijs ◽  
Hester E. de Melker ◽  
Mirjam J. Knol
Keyword(s):  
Public Health ◽  
The Netherlands ◽  
Meningococcal Disease ◽  
Surveillance System ◽  
National Level ◽  
Vaccination Status ◽  
Invasive Meningococcal Disease ◽  
Reference Laboratory ◽  
Public Health Response ◽  
Notification Data

Abstract Background Enhanced surveillance for confirmed cases of invasive meningococcal disease (IMD) was introduced in the Netherlands in 2003, in which reference laboratory data (NRLBM) are linked with notification data (OSIRIS). The quality of surveillance information is important for public health decision making. Our objective was to describe the system and evaluate it for data completeness and timeliness.
Methods
Cases reported in the surveillance system from 2004 to 2016 were included. For the notification data, we used information on serogroup, vaccination status, mortality, and country of infection as indicators for record completeness. Notification times to regional and national level were calculated using the reported dates available in the notification database. 
Results
A total of 2,123 cases were reported in the years 2004-2016, of which 1.968 (93%) were reported by the reference laboratory and 1.995 (94%) in the notification system. Of all cases, 1.840 cases (87%) were reported in both systems and could be linked. The serogroup was known in 86% of the notified cases, and was significantly higher (94%) in the years 2013-2016. Information on vaccination status, mortality and country of infection was available in 88%, 99% and 97% of notified cases, respectively. Regional notification of cases occurred within one working day for 86% of cases and 98% were notified nationally within three days. 
Conclusions
A well performing IMD surveillance system was demonstrated and serogroup completeness has improved over the years. Underlining the need for reporting to both the clinical and laboratory surveillance system remains important to further improve the overall performance in supporting public health response and vaccination policy.

scholarly journals Evaluation of the surveillance system for invasive meningococcal disease (IMD) in the Netherlands, 2004 – 2016

2019 ◽  
Author(s):  
Diederik A.H. Brandwagt ◽  
Arie van der Ende ◽  
Helma (W.) L.M. Ruijs ◽  
Hester E. de Melker ◽  
Mirjam J. Knol
Keyword(s):  
Public Health ◽  
The Netherlands ◽  
Meningococcal Disease ◽  
Surveillance System ◽  
National Level ◽  
Vaccination Status ◽  
Invasive Meningococcal Disease ◽  
Reference Laboratory ◽  
Public Health Response ◽  
Notification Data

Abstract Background Enhanced surveillance for confirmed cases of invasive meningococcal disease (IMD) was introduced in the Netherlands in 2003, in which reference laboratory data (NRLBM) are linked with notification data (OSIRIS). The quality of surveillance information is important for public health decision making. Our objective was to describe the system and evaluate it for data completeness and timeliness.
Methods
Cases reported in the surveillance system from 2004 to 2016 were included. For the notification data, we used information on serogroup, vaccination status, mortality, and country of infection as indicators for record completeness. Notification times to regional and national level were calculated using the reported dates available in the notification database. 
Results
A total of 2,123 cases were reported in the years 2004-2016, of which 1.968 (93%) were reported by the reference laboratory and 1.995 (94%) in the notification system. Of all cases, 1.840 cases (87%) were reported in both systems and could be linked. The serogroup was known in 86% of the notified cases, and was significantly higher (94%) in the years 2013-2016. Information on vaccination status, mortality and country of infection was available in 88%, 99% and 97% of notified cases, respectively. Regional notification of cases occurred within one working day for 86% of cases and 98% were notified nationally within three days. 
Conclusions
A well performing IMD surveillance system was demonstrated and serogroup completeness has improved over the years. Underlining the need for reporting to both the clinical and laboratory surveillance system remains important to further improve the overall performance in supporting public health response and vaccination policy.

Sign in / Sign up

Export Citation Format

Share Document